

**Correction to
Lancet Oncol 2019;
20: 408–19**

Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; **20**: 408–19—In this Article, IEO and IRCCS have been added to the Istituto Europeo di Oncologia affiliation of Franco Nolè. This correction has been made to the online version as of Sept 30, 2019.

**Correction to
Lancet Oncol 2019;
20: 1171–82**

Nené NR, Reisel D, Leimbach A, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. *Lancet Oncol* 2019; **20**: 1171–82—In this Article, IRCCS has been added to the Istituto Europeo di Oncologia affiliation of Nicoletta Colombo and Dorella Franchi. This correction has been made to the online version as of Sept 30, 2019.

**Correction to
Lancet Oncol 2019;
20: 1252–62**

Stacchiotti S, Ferrari S, Redondo A, et al. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2019; **20**: 1252–62—The affiliation of Javier Martin-Broto and the name of Nadia Hindi were incorrect. This correction has been made to the online version as of Sept 30, 2019.

**Correction to
Lancet Oncol 2019;
20: 1370–85**

Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *Lancet Oncol* 2019; **20**: 1370–85—In figures 2 and 3 of this Article, median and 95% CI data should have appeared in panel C and not in panel A. This correction has been made to the online version as of Aug 21, 2019.

Published Online
August 21, 2019
[http://dx.doi.org/10.1016/S1470-2045\(19\)30542-X](http://dx.doi.org/10.1016/S1470-2045(19)30542-X)